Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01703260 · ClinicalTrials.gov registry record · Phase 2
Safety and Efficacy of Roflumilast and Pioglitazone in Treating Adults With Nonalcoholic SteatoHepatitis
A Phase 2 study, sponsored by AstraZeneca.
- Terminated
- Registry status
- Phase 2
- Development phase
- 20
- Enrollment target
NCT01703260 is a Phase 2 study that was terminated before completion, run by AstraZeneca. The registered enrollment target is 20 participants.
The verdict
NCT01703260, a Phase 2 study, was terminated before completion, sponsored by AstraZeneca.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 20 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the effect of roflumilast and pioglitazone therapy on serum transaminase (ALT) levels in adults with Nonalcoholic SteatoHepatitis.
Interventions
- DRUG Placebo
- DRUG Roflumilast
- DRUG Pioglitazone
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2013-06 |
| Est. Completion | 2014-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01703260
The ClinicalTrials.gov registry entry for NCT01703260 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT01703260 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01703260 about?
NCT01703260 is a clinical study titled "Safety and Efficacy of Roflumilast and Pioglitazone in Treating Adults With Nonalcoholic SteatoHepatitis". The purpose of this study is to evaluate the effect of roflumilast and pioglitazone therapy on serum transaminase (ALT) levels in adults with Nonalcoholic SteatoHepatitis.
What is the current status of trial NCT01703260?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 20 participants. The study started on 2013-06. Estimated completion is 2014-09.
What interventions are being tested in trial NCT01703260?
The interventions under investigation include: Placebo (DRUG), Roflumilast (DRUG), Pioglitazone (DRUG).
Who is sponsoring clinical trial NCT01703260?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.